American Society for Transplantation and Cellular Therapy | Strategic Alliance Partners

Recent research found that the disialoganglioside 2–directed bispecific trifunctional antibody has 2 binding sites which allows for a mitigated T-cell anti-tumor response.

Alex Kradhim reviews how graft-versus-host disease can be maintained by tissue resident TCF-1+ T cells.

Alison Gulbis, PharmD, BCOP, discusses her experience of being a woman in the bone marrow transplant and cellular therapy field.

Rahul Banerjee, MD, FACP, discusses a recent presentation from the Tandem meeting regarding BCMA CAR T-cell therapy in patients with multiple myeloma.

Rahul Banerjee, MD, FACP, recounts the recent Tandem meeting by highlighting an interesting study involving cell phones and cell therapies.

Eleanor Mayfield, ELS, reviews the role of bispecific antibodies in hematologic malignancies.

Eleanor Mayfield, ELS, discusses FLT3-ITD minimal residual disease in acute myeloid leukemia.

Alex Kadhim investigates outcomes in infant patients who receive blood and marrow transplantation.

ASTCT recently published an article by Eleanor Mayfield, ELS, in their journal Nucleus discussing minimal residual disease negativity in patients with multiple myeloma.

ASTCT recently published an article in their journal Nucleus discussing extracorporeal photopheresis compared with acute graft-versus-host disease after receipt of hematopoietic stem cell transplant in children or young adults.

ASTCT recently published an article in their journal Nucleus detailing the use of mesenchymal stromal cells for the treatment of graft-versus-host disease

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

This article was written for and by CancerNetwork partner, the American Society for Transplantation and Cellular Therapy.

Mary Horowitz, MD, MS, discusses efforts to increase diversity in clinical trials for blood and bone marrow transplant.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

The following was recently published in ASTCT’s Nucleus publication. Follow @ATSTCT for the latest on all-things cellular therapy.

ASTCT recently published an article in their journal Nucleus detailing the use of killer immunoglobulin-like receptor–ligand mismatch and its impact on graft versus host disease.

ASTCT recently published an article in their journal Nucleus detailing the impact of genotype and voriconazole co-administration on tacrolimus trough concentration in pediatric β-thalassemia major patients following allogeneic hematopoietic stem cell transplantation.

Join ASTCT for a series of webinars that focus on topics relating to CAR T.

ASTCT recently published an article in their journal Nucleus detailing the EQUATE study and its use of itolizumab.

ASTCT recently published an article in their journal Nucleus detailing a simplified manufacturing process for CAR T cells.

ASTCT recently published an article in their journal Nucleus detailing CAR T therapy in patients with acute lymphoblastic leukemia.

ASTCT recently published an article in their journal Nucleus detailing the COVID-19 vaccine after CAR T therapy.

A recently published article on CAR T cells in patients with acute myeloid leukemia is featured by CancerNetwork's Strategic Alliance Partner ASTCT.

ASTCT recently published an article in their journal Nucleus detailing CAR T-cell in pediatric patients with brain cancer.

The latest episode of the ASTCT Talks features Rahul Banerjee, MD, on bone marrow transplant and CAR-T therapy.

The latest episode of the ASTCT Talks episode features a discussion from Andrés Gómez De León, MD, and Perla Colunga, MD, on outpatient haploidentical stem cell transplantation.

The latest episode of the ASTCT Talks episode features John DiPersio, MD, PhD, on emerging therapies in the treatment of acute myeloid leukemia.

Findings from a poster presentation at the 2021 Transplantation and Cellular Therapy Meetings of ASTCT and CIBMTR suggest the feasibility of successful vaccinations against coronaviruses in patients with hematologic malignancies following stem cell transplant.